- Truffle investment
- € 25M
Symetis is specialized in minimally invasive cardiac valves.
This characteristic makes the technology very tolerant with regard to the positioning of the implant before its complete release. ACURATE valves are designed to treat patients with severe and symptomatic aortic valve stenosis, who are considered at high risk of surgical valve replacement. Instead of open-heart surgery, the replacement valve is delivered by a transcatheteral percutaneous administration system. The ACURATE platform is known for its ease of use when implanting valves. Pre-acquisition the company had a turnover of €60M and was number 3 after Edwards and Medtronic. The company was sold in 2017 to Boston Scientific for a total amount of $435 million
Symetis receives CE certification in September.
First success for men - ACURATE TF.
Symetis receives CE marking approval for the ACURATE transcatheterotransfemoral aortic valve system neo™
In September, Symetis launches an initial public offering.
Symetis is now ranked 3rd, ahead of Boston Scientific in Germany, with an 11% market share.
Symetis is sold for $435 million to Boston Scientific.